Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

Published:2016-11-24 Issue:3 Volume:56 Page:441-447
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Bergqvist Michael¹²³,Holgersson Georg¹²,Bondarenko Igor⁴,Grechanaya Elena⁵,Maximovich Alexey⁵,Andor György⁶,Klockare Maria⁷,Thureson Marcus⁸,Jerling Markus⁷,Harmenberg Johan⁷

Affiliation:

1. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;

2. Gävle Hospital, Center for Research & Development, Uppsala University/County Council of Gävleborg, Gävle, Sweden;

3. Department of Radiation Sciences, Umeå University, Sweden;

4. Dnipropetrovsk Medical Academy, City Multi-Field Clinical Hospital #4, Dnipropetrovsk, Ukraine;

5. PSI, St. Petersburg, Russia;

6. PSI, Budapest, Hungary;

7. Axelar AB, Karolinska Institutet Science Park, Solna, Sweden;

8. Statisticon AB, Uppsala, Sweden

Funder

This study was financially supported by the private company Axelar AB.

Publisher